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The ORF3 protein of hepatitis E virus (HEV) contains a “PSAP” amino acid late domain motif, which
allows for interaction with the endosomal sorting complexes required for transport (ESCRT) pathway
aiding virion release. Late domain motifs are interchangeable with other viral late domain motifs in
several enveloped viruses, however, it remains unknown whether HEV shares this functional inter-
changeability and what implications this might have on viral replication. In this study, by substituting
heterologous late domain motifs (PPPY, YPDL, and PSAA) for the HEV ORF3 late domain (PSAP), we
demonstrated that deviation from the PSAP motif reduces virus release as measured by viral RNA in
culture media. Virus release could not be restored by insertion of a heterologous late domain motif or by
supplying wild-type ORF3 in trans, suggesting that the HEV PSAP motif is required for viral exit which
cannot be bypassed by the use of alternative heterologous late domains.
& 2015 Elsevier Inc. All rights reserved.Introduction
Hepatitis E virus (HEV) is a non-enveloped, single-stranded,
positive-sense RNA virus belonging to the family Hepeviridae
(Smith and Simmonds, 2014). HEV is transmitted via a fecal-oral
route through contaminated water and food (Kamar et al., 2014;
Van der Poel, 2014) and also as an emerging zoonotic threat
(Meng, 2013; Pavio et al., 2015, 2010) causing acute hepatitis in
immunocompetent and chronic hepatitis in immunocompromised
patients (Teshale et al., 2010). For these reasons, hepatitis E is
considered a public health concern especially in many developing
nations. Currently there are no FDA-approved diagnostics, anti-
virals, or vaccines on the market. In order to develop effective
antivirals and vaccines, it is imperative that different aspects of the
HEV life cycle be studied so that they can be explored for potential
therapeutic targets.
The HEV genome consists of three open reading frames (ORFs):
ORF1 encodes the nonstructural proteins containing methyl-
transferase (Magden et al., 2001), cysteine protease (Parvez andiences and Pathobiology, Vir-
13), 1981 Kraft Drive, Blacks-
x: þ1 540 231 3414.
roject.Khan, 2014; Karpe and Lole, 2011), helicase (Karpe and Lole, 2010a,
2010b), and RNA-dependent RNA polymerase (Agrawal et al.,
2001; Koonin et al., 1992) domains. The ORF1 also plays a role in
interaction with the host causing immunomodulation through
inhibition of type I interferon induction (Nan et al., 2014) and
aiding in viral adaptation to the host through the hypervariable
polyproline region (Purdy et al., 2012; Johne et al., 2014). ORF2
encodes the viral capsid protein (Tam et al., 1991; Reyes et al.,
1993), and ORF3 encodes a small, 13.5 kDa, multifunctional phos-
phoprotein (Cao and Meng, 2012; Ahmad et al., 2011). Although
not critical for virus infection in vitro (Emerson et al., 2006), the
ORF3 protein plays essential roles within the HEV lifecycle, and is
critical for viral infection in macaques and pigs (Graff et al., 2005;
Huang et al., 2007). The ORF3 protein interacts with a myriad of
host cellular proteins including SH3 domain containing proteins
involved in the MAPK pathway (Kar-Roy et al., 2004; Korkaya et al.,
2001), hemopoxin (Ratra et al., 2008), hypoxia-inducible factor 1
(Moin et al., 2009), ﬁbrinogen Bβ chain (Ratra et al., 2009), retinoic
acid-inducible protein I (Nan et al., 2014), α1-microglobulin,
bikunin, and hepsin (Tyagi et al., 2004, 2005; Wang et al., 2014;
Geng et al., 2013) aiding in prolonging cell survival, manipulating
the liver microenvironment, and contributing to overall HEV
pathogenesis.
Recently, HEV virions were shown to be associated with lipids
and this association was linked to a PSAP late domain motif within
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et al., 2008; Yamada et al., 2009). HEV is similar to the hepatitis A
virus in that both viruses appear to be released from cells into the
bloodstream as enveloped viruses which enables the virus to be
protected from the immune system before being excreted through
the intestinal tract (Feng et al., 2013). Once reaching the intestinal
lumen, these viruses then lose their envelopes prior to infecting
the next susceptible host cell.
Late or “L” domains, so named for their function late in the viral
assembly process, play a critical role in the formation of enveloped
viral particles from the plasma membrane of infected cells (Freed,
2002; Welsch et al., 2007). Most enveloped viruses including ret-
roviruses (Freed, 2002; Gottlinger et al., 1991), rhabdoviruses
(Craven et al., 1999), and ﬁloviruses (Schmitt and Lamb, 2004)
encode late domains in their viral genomes. Late domains are
characterized by a highly conserved amino acid motif known to
facilitate protein–protein interactions between viral and host cel-
lular proteins. Three canonical L domains have been studied to
great extent to date: P[TS]AP, PPXY, and YPDL. The P[TS]AP domain
binds to the TSG101 (ESCRT-I) gene which also binds to ubiquitin
(Sundquist et al., 2004) facilitating interaction with the ESCRT
machinery. The YPDL “L domain” binds to ALIX/AIP1 which also
interacts through TSG101 via its own PTAP motif (Strack et al.,
2003). PPXY domain binds Nedd4-like HECT-domain possessing
ubiquitin ligases which allows participation in the ESCRT pathway
without the necessity for TSG101 interaction. This pathway has
been shown to induce cellular membrane scission events through
a process believed to involve ubiquitination, resulting in the for-
mation of viral particles which are released from the cell (Zhadina
and Bieniasz, 2010). It is believed that the interactions between
components of the ESCRT pathway such as Alix, TSG101, and HECT
ubiquitin ligases are facilitated by arrestin-related trafﬁcking (ART)
proteins which have been found to be recruited to cellular sites of
viral budding (Rauch and Martin-Serrano, 2011).
It has been shown that there is a functional interchangeability
of these late domains for other virus systems. For example, the
human immunodeﬁciency virus (HIV) PSAP motif or the YPDL
motif of equine infectious anemia virus (EIAV) could be used to
induce the budding of Rous sarcoma virus which uses a PPPY late-
domain to initiate virus release (Parent et al., 1995). Other studies
have shown that the need to recruit ESCRT machinery through the
use of other co-factors can be bypassed by experimentally-driven
direct recruitment of the ESCRT machinery to allow for viral exit,
and ubiquitination of the viral structural protein itself enhances
virus release (Zhadina and Bieniasz, 2010). Taken together, the
available data suggest that viruses can make use of multiple
mechanisms to access the ESCRT pathway, regardless of the late
domain that is contained in their genome. Currently, it is unknown
if there is a functional interchangeability of the PSAP domain in
HEV with late domains used by other viruses.Fig. 1. A schematic diagram of substitutions introduced in the PxxP late domain
motif within the ORF2/3 reading frames of the Kernow-C1 P6 strain of HEV. Dia-
gram represents the full-length genome of HEV. Black line represents the viral
genomic RNA with 5’ cap and 3’ polyadenylation sequences. Boxes represent open
reading frames (ORFs) within the genome as labeled. Blowout shows the sequence
between nucleotides 5615-5650 with the ORF3 amino acid sequence showing
below, followed by the ORF2 reading frame. Mutations inserted in place of the
wild-type PSAP motif (underlined) are shown in bold in the nucleotide, ORF3, and
ORF2 reading frames.Results
The PSAP late domain motif is highly conserved among ORF3 proteins
from different HEV strains but lysine residues are absent
A BLAST search against the genotype 3 HEV Kernow strain ORF3
protein sequence yielded 258 novel ORF3 protein sequences
deposited within the GenBank database. Multiple sequence
alignment of the ORF3 sequences showed that there is a highly
conserved PSAP motif occurring at ORF3 amino acids 106-109 in
HEV genotypes 1–4 (Table S1). Additionally, in 46 out of 258 ORF3
sequences, the PSAP motif was duplicated at amino acid residues
96–99. Only two HEV strains, AFB71119 (a genotype 1 strain iso-
lated from India), and ACU12606 (a genotype 3 strain), lacked aPSAP motif at amino acids 106–109. Strain AFB71119 had no PSAP
motif within the entire ORF3 protein whereas strain ACU12606
had the second PSAP motif located at amino acids 96–99 (Table
S2). In addition to the conserved PSAP motif, there is a notable lack
of lysine residues with only a single lysine residue found in a
single genotype 4 HEV strain Q91V27 (Table S1).
Replacement of the HEV ORF3 PSAP motif with heterologous late
domain motifs
Overlap extension PCR was utilized to engineer a PPPY, YPDL,
and PSAA amino acid motif in place of the wild-type HEV ORF3
PSAP motif (Fig. 1). Due to the speciﬁcity and complexity of the
inserted amino acid sequences, we were not able to generate the
mutations silently within ORF2 because ORF2 overlaps ORF3.
Insertion of the PPPY motif within ORF3 caused a Q92P mutation
in ORF2 at amino acid position 92, an R93P mutation, and a P94L
mutation in ORF2. Similarly, generation of the ORF3 YPDL insertion
led to a S91L mutation, a Q92S mutation, and an R93G mutation in
ORF2. The insertion of the PSAA motif resulted in a P94R mutation
and an A96T mutation in ORF2 (Fig. 1).
HEV Kernow C-1 P6 mutant viruses containing substitutions in the
ORF3 PxxP motif are replication competent and infectious in vitro
In vitro-transcribed capped RNA from full-length clones of
wild-type, PSAA, YPDL, and PPPY HEV mutants were capable of
producing HEV ORF2 capsid protein when transfected into the
Huh7 S10-3 cells. Immunoﬂuorescent assay (IFA) using antibodies
against the HEV ORF2 capsid protein followed by ﬂuorescently-
labeled secondary antibodies produced speciﬁc signals for each
S.P. Kenney et al. / Virology 486 (2015) 198–208200wild-type and mutant HEV tested but not for the untransfected
mock sample (Fig. 2A). When quantiﬁed via ﬂow cytometry,
approximately 28–35% of the transfected cells including the PSAA,
YPDL, and PPPY HEV mutants produced ORF2 protein. When the
freeze-thawed cell lysates from these transfected Huh7 S10-3 cells
were used to infect HepG2/C3A cells, we again observed HEV-
speciﬁc ﬂuorescent signals after 5 days post-infection for wild-
type and mutant HEVs, indicating that these HEV mutants are
infectious although to a lower degree than the wild-type HEV
(Fig. 2B). When quantiﬁed, wild-type HEV infected 4.2% of the
cells, whereas PSAA mutant HEV infected 0.5% of the cells, PPPY
mutant infected 1.75% of the cells, and YPDL mutant infected 0.35%
of the cells (Fig. 2C) while all mock infected cells consistently
generated zero or negative values.
Wild-type and ORF3 PxxP HEV mutants localize to cellular endosomes
within Huh7 cells
In order to understand why the late domain mutants were less
infectious than the wild-type virus, we constructed ﬂuorescentFig. 2. Wild-type and ORF3 HEV mutants retain replication competence and infectivity
in vitro synthesized capped RNA transcripts fromwild-type or ORF3 mutant HEV probed
ﬂuorescein isothiocyanate (FITC) secondary antibody. (B) Freeze-thawed cellular lysat
transcripts were used to infect HepG2/C3A cells. At seven days post-infection, cells wer
antibody. (C) Flow cytometry quantiﬁcation of transfected Huh7 S10-3 (T) or infected He
probed with anti-ORF2 rabbit antibodies followed by anti-rabbit phycoerythrin (PE) secexpression vectors with the wild-type and mutant HEV ORF3s
tagged with ﬂuorescent molecules allowing visualization of ORF3
localization within the cells. HEV ORF3 localized to distinct regions
within the cellular cytoplasm and was not found within the nuclei
(Figs. 3 and S1). By co-transfecting the Huh7 cells with expression
vectors encoding endosomal markers, we were able to show that
the wild-type HEV ORF3 localized predominantly with Rab11, to a
much lesser extent Rab7, but not with TGN38 (Fig. 3), showing that
the localization of ORF3 is predominantly within recycling endo-
somes and to a lesser extent the late endosomes reconﬁrming
previous studies (Kenney et al., 2012; Chandra et al., 2008). The
ORF3 from YPDL, PPPY, and PSAA HEV mutants colocalized with
wild-type ORF3 when expressed within the same cell (Fig. S1).
As ORF3 is known to self-associate (Tyagi et al., 2001), it was
possible that wild-type ORF3 could function to properly redistribute
mutant ORF3. Therefore, we expressed each mutant strain alone
within cells expressing Rab7, Rab11, and TGN38 to determine the
subcellular localization of each individual wild-type and mutant
ORF3. The ORF3 YPDL, PPPY, and PSAA mutants each showed a
similar localization as the wild-type ORF3, predominantly recyclingin vitro. (A) Fluorescent microscopy images of Huh7 S10-3 cells transfected with
at 5 days post-transfection with anti-ORF2 rabbit antibodies followed by anti-rabbit
es from Huh7 cells transiently transfected with in vitro synthesized capped RNA
e probed with anti-ORF2 rabbit antibodies followed by anti-rabbit FITC secondary
pG2/C3A cells (I) from each mutant virus at 5-7 days post-transfection or infection
ondary antibodies.
Fig. 3. Wild-type and mutant HEV ORF3 proteins localize to cellular late and recycling endosomes. Huh7 cells were transfected with either wild-type HEV-eCFP or mutant
(PPPY, YPDL, PSAA) ORF3 HEV-eCFP constructs and were co-transfected with either Rab7-eYFP, a marker for late endosome (A), Rab-11-eYFP a marker for recycling
endosomes (B), or TGN38-eYFP a marker for the trans-golgi network (C). The eYFP ﬂuorescence is pseudo-colored green while the eCFP ﬂuorescence is pseudo-colored red.
Colocalization is seen as orange in the merged image.
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late endosomal localization than the other ORF3 proteins (Fig. 3A,
PSAA). The fact that the PSAA mutant also localized to the endo-
somes demonstrates that the localization of ORF3 to the cellular
endosomes is not dependent on the interaction between the PSAP
late domain and the ESCRT pathway proteins.
Wild-type HEV, YPDL and PPPY mutant ORF3 proteins colocalize with
the TSG101 protein and have positive Förster resonance energy
transfer (FRET) efﬁciencies suggesting interaction between these late
domains and TSG101
Co-expressing wild-type and mutant ORF3 eCFP with TSG101
eYFP in the same cell demonstrated colocalization of TSG101 and
each ORF3 within the cell (Fig. 4A). Though colocalization occurred
with all of the wild-type and mutant ORF3 proteins and TSG101,
this colocalization occurred less with ORF3 PSAA eCFP than
anticipated since we did not expect PSAA to interact with either
TSG101 or the rest of the ESCRT machinery.
To further determine whether ORF3 interacts with TSG101, we
performed acceptor photobleaching FRET which is a biophysicalnon-radiative transfer of energy between ﬂuorescent molecules
with overlapping excitation and emission spectra that are brought
within a distance of 1-10 nm of each other consistent with a bio-
logically relevant physical interaction (Jares-Erijman and Jovin,
2006; Sekar and Periasamy, 2003; Kenney et al., 2008; Siegel et al.,
2000). The FRET efﬁciencies for the negative control of eCFP and
eYFP was 6.18%, whereas wild-type ORF3 and TSG101 produced a
FRET efﬁciency signiﬁcantly greater than eCFP and eYFP (21.49%,
P¼0.0007). The FRET efﬁciency found for the PSAA mutant was
not signiﬁcantly different than the FRET efﬁciency of the negative
control (9.05%, P¼0.265). The FRET efﬁciencies for ORF3 PPPY
(20.89%, Po0.0001) and YPDL (13.25%, P¼0.013) were sig-
niﬁcantly greater than eCFP and eYFP alone, suggesting that they
were within 10 nm of each other, thus indicative of an interaction
between these ORF3 proteins and TSG101 (Fig. 4B). The fact that
these late domains were found in such close proximity to the
TSG101 motif implies that they are likely interacting with each
other. This was expected with the wild-type HEV ORF3 as the PSAP
motif is thought to interact directly with TSG101 but is unexpected
in the cases of PPPY and YPDL, as these domains are thought to
interact with other components of the ESCRT machinery. PSAAwas
Fig. 4. Wild-type and mutant ORF3s colocalize and interact with the host protein
cellular protein tumor suppressor gene 101 (TSG101). (A) TSG101 tagged with eYFP
colocalizes with HEV ORF3 proteins tagged with eCFP. (B) Förster resonance energy
transfer (FRET) demonstrates that TSG101 is within a biologically relevant distance
to be interacting with wild-type, PPPY, YPDL, but not PSAA-containing ORF3 pro-
teins tagged with eCFP. Asterisks (*) indicate signiﬁcantly greater FRET efﬁciencies
than eCFP-eYFP control (Po0.05).
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studies showing that this mutation had release defects (Kenney
et al., 2012; Nagashima et al., 2011).
PPPY, YPDL, and PSAA HEV mutants have signiﬁcantly decreased viral
release compared to wild-type HEV
Since we demonstrated that each PSAP ORF3 substitution
mutation was still capable of interacting with TSG101 and hence
the ESCRT pathway, we next determined if they were capable of
allowing virus release from the cell. In order to determine virus
release, we performed HEV-speciﬁc qRT-PCR on RNA isolated from
cellular media and lysates separately, and then compared the
amount of viral RNA released into the media to the total level ofRNA expression in media and lysate collected from separate
samples on days 5, 6, and 7 then combining the results taken over
these days. Wild-type HEV had the most viral RNA in the media
with 8.25% of the total RNA being released into the cell culture
media, and as expected the PSAAORF3 mutant had the least
amount of RNA released into the media (0.76%) (Fig. 5A). The HEV
mutants containing the PPPY ORF3 and YPDL substitutions
released signiﬁcantly less viral RNA than that of the wild-type
virus (1.30%, P¼0.039 and 1.32%, P¼0.031, respectively).
Density of cell culture-derived HEV virions
Cell culture supernatants harvested from cells transfected with
wild-type capped HEV RNA at 5 days post-transfection pre-
dominantly banded at densities of 1.15–1.16 g/ml (21%) and 1.25 g/
ml (20%) (Fig. 6, wild-type), consistent with the ﬁndings of Taka-
hashi et al (Takahashi et al., 2010) in which our sample contained
both lipid associated (1.16 g/ml) and non-lipid associated (1.25 g/
ml) HEV virions. Disruption of the PSAP ORF3 late domain motif
led to a dramatic shift of the HEV bands to the 1.25 g/ml fraction
(44%) compared to only 1% remaining within the 1.16 g/ml fraction
(Fig. 6, PSAA). Insertion of the YPDL and PPPY motifs led to a
higher percentage of HEV RNA at the 1.16 g/ml peak than PSAA
(6.7% and 4.8%, respectively) and retained wild-type percentages
of HEV RNA at the 1.25 g/ml peaks (18.2% and 29.3%, respectively).
The YPDL mutant contained an intermediate peak (24.6%) at
1.19 g/ml, and PPPY mutant contained an intermediate peak
(23.6%) at 1.21 g/ml, suggesting a certain level of association with
lipids was present but not to the extent of wild-type HEV (Fig. 6,
YPDL and PPPY).
Mutations within the ORF2 contribute to the reduction in virus
release from the cell
As we were not able to restore viral release to wild-type levels
with either the PPPY or the YPDL substitutions, we wanted to
determine whether viral factors outside of ORF3 could be con-
tributing factors to viral RNA release from the cell. Since both the
YPDL and PPPY substitutions also altered amino acids Q92 and R93
within the ORF2 reading frame (Fig. 1), we wanted to assess
whether these amino acid substitutions within ORF2 could be
contributing to a decrease in virus release. To test this, we gen-
erated Q92L and R93C mutations within ORF2 without altering the
amino acid sequences within ORF3 (Fig. 1Q92L and R93C). When
these mutants were assayed for viral RNA release, both appeared
to be numerically reduced from wild-type, ORF2 Q92L released
3.36% of its viral RNA into the media and ORF2 R93C released 1.85%
of its viral RNA into the culture media (Fig. 5B), however neither
was signiﬁcantly different from wild-type (WT:Q92L, P¼0.26; WT:
R93C, P¼0.13). Additionally, the amount of viral RNA released by
ORF2 Q92L and R93C were signiﬁcantly greater than the release of
the PSAA mutation (P¼0.025 and 0.0272, respectively), suggesting
that the impact of these ORF2 mutations was minor but, as we
were not capable of silently recapitulating the exact mutations
found in the PPPY and YPDL substitutions, we cannot rule out
more adverse effects on virus release from the speciﬁc amino acids
found within our ORF3 substitution mutant's capsids.
Addition of ORF3 protein in trans was not sufﬁcient to restore release
of virus containing the PSAA ORF3 mutation
In order to further rule out mutations within the ORF2 protein
affecting viral release, we attempted to use a gain of function assay
by providing wild-type ORF3 protein in trans by transient trans-
fection of cells previously transfected with either wild-type or
PSAA mutant HEV viral RNA and then assessed the amount of
Fig. 5. Substitutions within the HEV ORF3 PSAP motif do not restore virus release
and cannot be complemented by providing ORF3 protein in trans. (A) Quantitative
reverse transcription real time PCR (qRT-PCR) using primers speciﬁc for HEV RNA
from samples taken from infected cell culture supernatant compared to RNA within
the cellular lysate demonstrated that disruption of the PSAP motif decreases the
ability of HEV to be released into the media (PSAA compared to wild-type). Sub-
stitution PPPY and YPDL were not capable of restoring release to wild-type levels.
(B) Silent mutation of the ORF3 reading frame to insert a Q92L and R93C amino acids
in ORF2 while retaining the PSAP motif within ORF3 reduce levels of virus release.
(C) Cells infected with either wild-type or PSAA ORF3 mutants subsequently trans-
fected with plasmid DNA expressing wild-type ORF3 GFP or ORF3PSAAGFP were not
capable of restoring or augmenting release of wild-type or PSAA mutant virus as
assessed by titering the amount of virus released over a period of 24 h on naïve
HepG2/C3A cells. Asterisks (*) indicate signiﬁcantly lower than wild-type (Po0.05).
Octothorpes (#) indicate signiﬁcantly greater than PSAA mutant (P40.05).
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virus produced enough particles to infect 3.51% of HepG2/C3A
cells, wild-type plus ORF3GFP produced particles which infected
1.89% of the HepG2/C3A cells, and wild-type with PSAAORF3GFP
produced enough particles to infect 1.32% of the HepG2/C3A cells,
none of which was signiﬁcantly different from one another
(Fig. 5C). PSAA mutant alone produced particles capable of
infecting 0.59% of the HepG2C3a cells, signiﬁcantly less than wild-
type alone (P¼0.048). PSAA with wild-type ORF3GFP produced
particles capable of infecting 1.045% of the HepG2/C3A cells and
PSAA plus PSAAGFP produced particles capable of infecting 0.94%
of the HepG2/C3A cells, not signiﬁcantly greater than the PSAA
mutant alone (Fig. 5C). Additionally, there was no signiﬁcant dif-
ference between both wild-type plus ORF3GFP and wild-type plus
PSAAGFP compared to PSAA alone suggesting that overexpression
of a C-terminally tagged ORF3 was detrimental to virus release.
When observing viral RNA release, there was also no signiﬁcant
difference between wild-type and wild-type plus ORF3GFP or
wild-type plus PSAAORF3GFP, and there were no signiﬁcant dif-
ference in viral RNA release between PSAA, PSAA plus ORF3GFP,
and PSAA plus PSAAORF3GFP (data not shown).Discussion
Much of the assembly stage during HEV virion formation
remains unexplored. Previous studies have shown that other
viruses are able to use alternative amino acid domains in order to
bypass speciﬁc TSG101 interactions and allow for viral exit (Zha-
dina and Bieniasz, 2010; Parent et al., 1995). In this study, we
investigated the mechanisms of envelopment and release phases
of HEV assembly through substitutions of heterologous PPPY and
YPDL late domains in place of the HEV ORF3 wild-type PSAP late
domain. In an effort to determine if HEV shares this functional
interchangeability with other heterologous late domains, multiple
approaches were used to create different virus mutants and then
examine how they replicated, how their proteins interacted with
the host ESCRT pathway, and how these mutations affected their
ability to exit cells.
The results from this study showed that, when the HEV ORF3
PSAP motif is substituted with heterologous late domain motifs,
the resulting substitution mutants of HEV were replication com-
petent, producing viral capsid protein, and the ORF3 protein of the
HEV mutants was capable of localizing to the same cellular orga-
nelles as the wild-type HEV ORF3 protein. However, the HEV
ORF3-speciﬁc PSAP motif was required for the virus to efﬁciently
exit host cells. Without this interaction, viral exit was signiﬁcantly
impaired as seen with the PPPY and YPDL ORF3 substitution
mutants. These results also imply that this speciﬁc interaction
between PSAP and the ESCRT pathway is crucial for viral exit and
spread to other host cells. Unlike retroviral structural proteins
which can be directly ubiquitinated by host factors to aid in par-
ticle release (Zhadina and Bieniasz, 2010), direct ubiquitination of
HEV ORF2 (which previous studies have shown that it does not
appear to be ubiquitinated (Surjit et al., 2007) or direct ubiquiti-
nation of HEV ORF3 (as there are almost no mammalian HEV
strains possessing lysine) likely does not play a role in HEV
envelopment and release. Therefore, future experiments could
explore blocking this speciﬁc interaction as a potential antiviral
target.
We demonstrated that the PSAP late domain is not required for
cellular localization of ORF3 to endosomes, as evidenced by the
fact that all the HEV mutants were able to localize to endosomal
vesicles. This implies that interaction with the ESCRT machinery is
not required for localization to endosomes and suggests that the
ESCRT machinery may more speciﬁcally be required solely for HEV
Fig. 6. Sucrose density centrifugation of HEV particles from the supernatants of Huh7 cells transfected with wild-type and HEV ORF3 mutants. Twenty-one fractions from a
10–60% sucrose gradient overlaid with cell culture media from Huh7 cells transfected with the indicated full-length viral RNAwere collected. RNAwas isolated, quantiﬁed via
qRT-PCR and plotted against the density of the fraction determined via refractometry. RNA is plotted as percentage of the total RNA measured from all fractions. Dotted lines
were inserted at 1.16 g/ml and 1.25 g/ml as this was previously published to coincide with lipid-associated virions and unenveloped virions, respectively (Takahashi et al.,
2010).
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protein. The results from our FRET results yield interesting ﬁndings
in that we did not expect the PPPY substitution mutant to interact
with TSG101 as this motif is known to interact with the NEDD4
family of ubiquitin ligases rather than TSG101. It may be possible
that TSG101 localization to the same endosomal compartment as
the PPPY ORF3 mutant is causing an artiﬁcial FRET signal due to
macromolecular crowding. The small increase that was not sig-
niﬁcantly different than eCFP/eYFP alone in the PSAAORF3-TSG101
would also argue that this could be occurring or the interaction of
the PPPY motif with the NEDD4 family may create some types of
higher ordered complex which places PPPY ORF3 in very close
proximity to TSG101. Further research is required to determine
whether these PPPY and YPDL motifs are indeed directly inter-
acting with TSG101 and if so, why this interaction is not capable of
wild-type levels of virus particle release.
Though the HEV mutants in this study were able to infect,
replicate and localize in vitro, the use of real time qPCR demon-
strated that the late domain is required for viral exit from the host
cell. By determining the ratio of viral RNA that was found in the
cell lysates compared to cellular media in the HEV mutants, we
found that mutant HEV viral exit from Huh7 cells was signiﬁcantly
reduced when compared to wild-type HEV. This was unexpected,
as it was thought that HEV would show functional interchange-
ability in late domains similar to other viruses.
It is intriguing that we were not capable of restoring PSAA HEV
virus release to wild-type levels by simply providing ORF3 protein
in trans. Several explanations for this phenomenon could be pro-
posed. The simplest explanation is that the ORF3 protein requires
an unhindered C-terminus to contribute to the release stage of the
virus assembly process, and that by using an ORF3 protein with a
ﬂuorescent tag rendered it unable to complement the PSAA
mutation. This is evident in Fig. 5C when wild-type virus is
expressed with either ORF3GFP or PSAAGFP, where wild-typealone becomes statistically insigniﬁcant from PSAA virus alone. A
second possibility is that the PSAA mutations act as a dominant
negative mutation and if any PSAA ORF3 is present, the budding
efﬁciency is altered. We do see a numerical decrease in the
number of infectious wild-type particles released when cotrans-
fected with PSAA GFP, although it was not statistically different. It
could also be that supplying an overabundance of ORF3 interferes
with other aspects of the virus assembly pathway as we saw a
decrease, although not statistically signiﬁcant, in infectious parti-
cles simply by co-expressing wild-type ORF3GFP protein with
wild-type virus. More experiments will be necessary in the future
to deﬁne why we could not complement the ORF3 mutations with
wild type ORF3 protein supplied in trans.
Due to its ability to cause acute hepatitis in the general popu-
lation, fulminant hepatitis in pregnant women, and chronic
hepatitis in immunosuppressed individuals, HEV is an important
but extremely understudied pathogen. It is imperative that we
understand key aspects of HEV infection and viral spreading in
order to devise effective preventive and control strategies against
HEV. By demonstrating that the PSAP motif in the late domain of
HEV ORF3 is required for viral exit and cannot be bypassed by the
use of alternative heterologous late domains, it highly suggests
that the PSAP-TSG101 interaction is speciﬁcally required for virion
release. In this way, attempting to antagonize or block this inter-
action may block virion exit and the spread of virus from cell to
cell, which could have a clinical impact on the course or severity of
HEV infection. By identifying this speciﬁc interaction required for
viral spreading, we have identiﬁed a potential antiviral target.
Previous studies have been successful at blocking the Gag-TSG101
interaction in HIV with the use of small molecule therapeutics
(Tavassoli et al., 2008), and inhibiting the PPxY-Nedd4 interaction
(Han et al., 2014) in other viruses. Such targeted inhibitions of the
ESCRT machinery and its components should be explored for HEV
in future studies.
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Expression vectors, plasmids, and cells
The pBlueScript SK (þ) vector containing the Kernow-C1 pas-
sage 6 (P6) genotype 3 HEV infectious cDNA clone has been pre-
viously described (Shukla et al., 2012). Fluorescent vectors used for
the ORF3 expression in this study were enhanced cyan ﬂuorescent
protein (eCFP) and enhanced yellow ﬂuorescent protein (eYFP)-N1
vectors (Clontech, Mountain View, CA). The Huh7 S10-3 human
hepatoma cell line (a gift of Suzanne U. Emerson, NIAID, NIH,
Bethesda, MD) and HepG2/C3A hepatocellular cell line (ATCC:
CRL10741) were used for localization and infectivity assays.Construction of mutant HEV viruses containing substitutions in the
HEV ORF3 PxxP motif
Using two rounds of overlap extension PCR (OEPCR) with
pBlueScript Kernow-C1 passage 6 HEV infectious clone as the
template, HEV mutants with PPPY and YPDL motifs substituted for
the wild-type PSAP motif were created. Additionally, a PSAA
mutant was created to act as a negative control. For generation of
the PPPY mutant, primer pairs JLW10/JLW2 and JLW3/JLW11
(Table 1) were used for the ﬁrst round OEPCR, and primer pair
JLW10/JLW11 was used for the 2nd round PCR. After OEPCR, a PPPS
mutation was veriﬁed by sequencing. Primer pair JLW1/JLW4 was
used to correct PPPS to PPPY in an additional, third round of PCR-
directed mutagenesis. For generation of YPDL mutant, primer pairs
JLW10/SPK348 and SPK349/JLW11 were used for the ﬁrst round
OEPCR and primer pair JLW10/JLW11 was used for 2nd round PCR
(Table 1). For generation of PSAA mutant, primer pairs JLW10/JLW8
and JLW9/JLW11 were used for the ﬁrst round OEPCR and primer
pair JLW10/JLW11 was used for 2nd round OEPCR (Table 1). For
generation of the ORF2 Q92L mutation, primer pairs JLW10/
SPK575 and SPK576/JLW11 were used for the ﬁrst round OEPCR
followed by JLW10/JLW11 for the second round PCR ampliﬁcation
(Table 1). Generation of the ORF2 R93C mutation was done using
primer pairs JLW10/SPK577 and SPK578/JLW11 for the ﬁrst round
PCR followed by JLW10/JLW11 for the second round PCR ampliﬁ-
cation (Table 1). Following the OEPCR mutagenesis, the PCRTable 1
Oligonucleotide sequences utilized in OEPCR mutagenesis, qRT-PCR, and for cloning int
Name Sequence (5’-3’) Funct
SPK337 CATCATCTCGAGCCATGGGATCACCATGCG Used
SPK341 CATCATAAGCTTGTACAGGGGCTGTGTCAGG Used
JLW10 CAGTGTTTGCTGCCGCTG Exter
JLW11 GGAGGTAGCCTCCTCCTC Exter
JLW8 GCAGTGGAGCGGCGC Creat
JLW9 GCGCCGCTCCACTGC Creat
SPK348 AAGGTCCGGATAACTGGTCACGCCAAGCGG Creat
SPK349 TATCCGGACCTTCCGCTGCCCCCCG Creat
JLW2 ATAGGGGGGGGGACTGGTCACGCC Creat
JLW 3 GGCGTGACCAGTCCCCCCCCCTAT Creat
JLW1 CTGATGTTGTGCGTTTCGC PPPS
JLW4 CATACATAGGGTTGGTGGACG PPPS
SPK575 GACCAGTCCCTCCGCC Creat
SPK576 GGCGGAGGGACTGGTC Creat
SPK577 GACCAGTCCCAGTGCCC Creat
SPK578 GGGCACTGGGACTGGTC Creat
SPK373 GGTGGTTTCTGGGGTGAC qRT-P
SPK374 AGGGGTTGGTTGGATGAA qRT-P
SPK375 56-FAM/TGATTCTCA/ZEN/GCCCTTCGC /3IABKFQ qRT-P
SPK592 GCGATGCTTATGAGGAGTCA qRT-P
SPK593 GGCCGAGAGAGAAGTTGTTC qRT-P
SPK594 56-FAM/TGCTTGCTG/ZEN/CCGCTGTGTCA/ 3IABKFQ qRT-Pproducts were ligated into the Kernow-C1 P6 viral vector and
veriﬁed by sequencing.
In vitro transcription of full-length capped viral genomic RNA,
transfection of Huh7 S10-3 cells, and infection of HepG2/C3A cells
The pBluescript Kernow-C1 P6 HEV infectious clone and its
derived subsequent mutants were linearized via MluI restriction
enzyme digest, proteinase K treated, then puriﬁed via phenol
chloroform extraction and ethanol precipitation. Linearized DNA
was used as the template for in vitro transcription via a T7 Ribo-
max RNA transcription kit (Promega) following the manufacturer's
protocol for capped RNA synthesis using anti-reverse cap analogue
(ARCA) RNA (Tri Link Biotechnologies). RNA transcripts were
visualized via gel electrophoresis on 0.8% agarose gels, and sub-
sequently puriﬁed via Qiagen RNA columns and treated with turbo
DNase (Ambion). Reactions were subjected to qRT-PCR and nor-
malized based on CT values prior to transfection. Huh7 subclone
S10-3 cells noted for their ability to support HEV replication were
used for initial transfection. Normalized in vitro-transcribed cap-
ped RNA was transfected into Huh7 S10-3 cells using a Trans-IT-
mRNA transfection kit (Mirus). Cells at day 2 post transfection
were passaged 1:2 onto two new T25 ﬂasks. Five to six days post
transfection ﬂasks of cells were frozen at 80 °C and thawed
3 times. Cellular debris was spun out at 1000g for 10 min with the
resultant supernatant being used to infect naïve HepG2/C3A cells.
Equivalent volumes of cleared cellular lysate was incubated with
naïve HepG2/C3A cells for 4 h at 37 °C before changing to fresh
primary growth media and allowing the cells to grow for an
additional 4–5 days.
Immunoﬂuorescence assays (IFA) and ﬂow cytometry
Four to ﬁve days post-transfection or infection cells were
trypsinized and either re-seeded onto chamber slides and ﬁxed
one day after re-seeding using 80% methanol, or cells were spun
down at 525g and resuspended in 100% methanol at 4 °C for
15 min then frozen at 80 °C until processed for ﬂow cytometry.
For confocal imaging, cells were probed using anti-HEV ORF2
rabbit antibodies followed by goat anti-rabbit ﬂuorescein iso-
thiocyanin (FITC) secondary antibodies (KPL). Cells were stainedo expression vectors.
ion
to amplify ORF3 for insertion into ﬂuorescent vector using Xho1 restriction site.
to amplify ORF3 for insertion into ﬂuorescent vector, HindIII restriction site.
nal OEPCR for ORF3 mutations.
nal OEPCR for ORF3 mutations.
ion of PSAA mutant, round 1 OEPCR.
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phate buffered saline (PBS) for 5 min at room temperature,
washed twice more in PBS, and mounted on slides using aqua
polymount (Polysciences Inc.). Fluorescence microscopy was per-
formed using a Nikon TE2000 sweptﬁeld confocal system using
Elements software (Nikon, USA). To visualize the FITC and DAPI
signals, an X-cite series 120 light source was used for excitation in
conjunction with a DAPI-FITC-TRITC emission ﬁlter cube and
Photometrics CoolSNAP HQ2 camera. For ﬂow cytometry, cells
were pelleted out of methanol and resuspended in 300ul of
blocking solution (1.0% nonfat dried milk, 1.0% Odyssey Block
(Licor Biosciences), 1.0% normal goat serum, and 0.1% Triton X-100)
at 37 °C for 30 min. Cells were probed using anti-HEV ORF2 rabbit
antibodies for 1 h at 37 °C, followed by 2 washes with PBS, incu-
bation with goat anti-rabbit IgG (HþL) phycoerythrin conjugated
secondary antibody (Life Technologies) at a 1:1000 dilution for
30 min at 37 °C, followed by 2 more washes with PBS. Cells were
analyzed with a FACS Aria II (BD Biosciences) and Flow Jo software.
A minimum of 20,000 events were recorded with gates being set
based on mock samples returning the lowest amount of back-
ground signal with positive signal being subtracted from all test
samples. Randomly tested mock samples returned no positive
signals.
Construction of recombinant vectors expressing ﬂuorescently-tagged
ORF3 fusion proteins and determination of sub-cellular localization of
wild-type and mutant ORF3
HEV Kernow-C1 P6 plasmids containing wild-type ORF3 or
ORF3 mutants containing PPPY, YPDL, and PSAA motifs in place of
the wild-type PSAP motif were ampliﬁed using primers SPK337
and SPK341 (Table 1). These primers were used to create XhoI and
HindIII restriction sites to clone ORF3 in frame with eYFP or eCFP.
All mutations were conﬁrmed via sequencing. Huh7 S10-3 cells
were co-transfected with eYFP expression vectors containing
intra-cellular organelle markers for recycling endosomes (Rab11-
eYFP) (Guignot et al., 2004), late endosomes (Rab7-eYFP) (Guignot
et al., 2004), and trans Golgi network (TGN38-eYFP) (Sherer et al.,
2003) using lipofectamine LTX reagent (Invitrogen) and TSG101-
eYFP (Johnson et al., 2005). Cells were ﬁxed 17–24 h post-trans-
fection using 4% paraformaldehyde and mounted to slides using
aqua polymount. Confocal microscopy was performed using a
Zeiss LSM 510 confocal microscope with Zen 2009 software (Zeiss,
USA) to look for overlap between eCFP and eYFP ﬂuorescence to
determine the subcellular localization of the wild-type HEV ORF3
and mutant ORF3. eYFP signals were acquired using the 514 nm
laser setting and eCFP signal was obtained using the 458 nm laser
settings using a Plan-Apo 63X oil immersion lens.
Confocal microscopy and Förster resonance energy transfer (FRET)
Huh7 S10-3 cells grown on coverslips were transfected using
lipofectamine LTX. At 18–24 h post-transfection, cells were ﬁxed in
4% paraformaldehyde and mounted using aquapolymount (Poly-
sciences Inc.). Cells were imaged on a Zeis LSM510 confocal
microscope using a plan-apo 63X oil immersion objective. eCFP
ﬂuorophores were excited using 458 nm light and eYFP was
excited using 514 nm.
For FRET assay, cells were initially imaged, bleached for 11–16
iterations of 100% 514 nm laser intensity. Cells were bleached to
30% or less of initial eYFP intensity. FRET intensity was calculated
as (Donor Post corrected for non-speciﬁc bleaching-Donor Pre)/
Donor Pre *100. A minimum of 10 total cells were analyzed for
each construct from at least two separate transfections.RT-PCR detection of HEV RNA released into cell culture media
T25 ﬂasks containing Huh7 S10-3 cells were transfected with
capped HEV RNA transcripts using the Trans-IT mRNA transfection
kit (Mirus) and washed twice with PBS 24 h post-transfection. At
two days post-transfection, cells were removed from the ﬂask
using 2 ml of 0.25% trypsin and 4 ml of Dulbecco's modiﬁed eagle's
media (DMEM) with 10% fetal bovine serum (FBS). Approximately
500 ml of cells were replated onto 12 well dishes. Media was har-
vested from each well at 5, 6, and 7 days post-transfection. Cellular
debris was spun out of the media (10,000g for 1 min). Cells were
removed from the plate using 500 ml of trypsin and 500 ml of
DMEM/10% FBS. Samples were frozen at 80 °C until processed.
Viral RNA was extracted from media and lysates using a viral RNA
isolation kit (Zymo). RNA was DNase-treated using a turbo DNA-
free kit (Life Technologies). Quantitative real time qRT-PCR was
performed using a SensiFAST real-time PCR kit (Bioline, USA) using
primers SPK373 and SPK374 with probe SPK375 (Table 1) (Jothi-
kumar et al., 2006) to determine the amount of RNA released into
the media compared to the total RNA expression in each well.
Puriﬁed in vitro transcribed full-length viral RNA transcripts from
either genotype 1 or genotype 3 HEV were quantiﬁed via spec-
trophotometry, serially diluted from 0.01 ng to 0.00000001 ng,
and used in the RT-PCR reaction to generate a standard curve to
which the unknown samples were compared to generate absolute
values for the quantity of HEV RNA in each tested sample. Once the
absolute quantity of RNA was generated from each sample, the
amount of viral RNA in the media was divided by the total amount
of RNA in both the media and lysate giving us a ratio of total viral
RNA released from the cell compared to the amount of total RNA in
both media and lysate.
Complementation of HEV RNA release with ORF3 provided in trans
T25 ﬂasks containing Huh7 S10-3 cells were seeded and
transfected with wild-type or PSAA HEV RNA as described for RT-
PCR detection of HEV RNA release. On day 5 post-transfection, cells
were transfected with either eYFP vector alone, wild-type ORF3
eYFP, or PSAA ORF3 eYFP. Transfected cells were washed three
times at 4–6 h post-transfection, and 0.2 ml of DMEM/10%FBS was
added to each well at 12 h post-transfection. Transfected cells
were allowed to grow for another 24 h before media and lysates
were harvested separately and stored at 80 °C until processed.
Equivalent volumes of media were used to infect 1.5104 HepG2/
C3A cells plated on 48 well dishes in quadruplicate. Cells at two
days post-infection were split 1:2 and allowed to grow for an
additional 4 days before being removed from the plate and pro-
cessed for ﬂow cytometry.
Sucrose density gradient equilibrium centrifugation
A density gradient was formed in an SW50Ti tube (Beckman
Coulter Inc., Fullerton CA) containing 0.8 ml 60% sucrose [wt/wt],
0.6 ml of 50%, 40%, 30%, and 20% [wt/wt] sucrose, and 0.3 ml of
10% sucrose in PBS (Takahashi et al., 2010). One hundred micro-
liters of each sample (wild-type HEV Kernow P6, PPPY, YPDL, and
PSAA) was layered onto the top of each gradient and overlaid with
0.4 ml of PBS. Samples were centrifuged at 179,200g at 4 °C for
19 h, and 200 ml aliquots were removed from the top of the gra-
dient. The density of each fraction was measured via refracto-
metry. RNA was isolated from 100 ml of each fraction using a ZR
viral RNA kit (Zymo Research) and the amount of vRNA in each
fraction was determined using quantitative real-time qRT-PCR
using the SPK373, SPK374, and SPK375 primer/probe set (Table 1).
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